Health Catalyst (NASDAQ:HCAT) Price Target Cut to $8.00

Health Catalyst (NASDAQ:HCAT - Free Report) had its price target cut by Evercore ISI from $9.00 to $8.00 in a research note published on Tuesday, Benzinga reports. They currently have an outperform rating on the stock.

HCAT has been the subject of several other research reports. Wells Fargo & Company reduced their price target on shares of Health Catalyst from $14.00 to $13.00 and set an overweight rating for the company in a report on Friday, May 10th. Piper Sandler dropped their target price on Health Catalyst from $15.00 to $14.00 and set an overweight rating on the stock in a research report on Thursday, June 6th. Canaccord Genuity Group reissued a buy rating and issued a $11.00 price target on shares of Health Catalyst in a research report on Tuesday, May 21st. KeyCorp reaffirmed a sector weight rating on shares of Health Catalyst in a research report on Wednesday, April 10th. Finally, Cantor Fitzgerald reissued an overweight rating and set a $16.00 price target on shares of Health Catalyst in a research report on Wednesday, April 10th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Health Catalyst presently has an average rating of Moderate Buy and a consensus price target of $11.91.

Health Catalyst Stock Down 1.3 %

HCAT traded down $0.08 on Tuesday, reaching $6.14. 379,418 shares of the company traded hands, compared to its average volume of 600,552. The company has a market cap of $362.44 million, a P/E ratio of -3.36 and a beta of 1.32. Health Catalyst has a one year low of $5.45 and a one year high of $14.37. The firm has a fifty day simple moving average of $6.50 and a two-hundred day simple moving average of $7.79.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. Health Catalyst had a negative return on equity of 11.86% and a negative net margin of 35.56%. The company had revenue of $74.72 million for the quarter, compared to analysts' expectations of $74.81 million. On average, equities analysts forecast that Health Catalyst will post -0.4 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Daniel Lesueur sold 5,208 shares of the firm's stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $6.15, for a total transaction of $32,029.20. Following the sale, the chief operating officer now directly owns 155,215 shares in the company, valued at approximately $954,572.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders sold 9,279 shares of company stock worth $58,742. Company insiders own 2.70% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Kennedy Capital Management LLC purchased a new stake in Health Catalyst during the 1st quarter valued at about $8,780,000. Impax Asset Management Group plc increased its holdings in shares of Health Catalyst by 52.0% in the fourth quarter. Impax Asset Management Group plc now owns 1,754,475 shares of the company's stock valued at $16,246,000 after purchasing an additional 600,000 shares during the last quarter. Primecap Management Co. CA increased its holdings in shares of Health Catalyst by 26.7% in the fourth quarter. Primecap Management Co. CA now owns 1,419,577 shares of the company's stock valued at $13,145,000 after purchasing an additional 299,139 shares during the last quarter. Essex Investment Management Co. LLC purchased a new position in Health Catalyst during the first quarter worth approximately $1,848,000. Finally, ClariVest Asset Management LLC boosted its stake in Health Catalyst by 303.9% during the first quarter. ClariVest Asset Management LLC now owns 282,325 shares of the company's stock worth $2,126,000 after buying an additional 212,425 shares during the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.